Shopping Cart
- Remove All
- Your shopping cart is currently empty
bPiDI is an innovative selective antagonist of α6β2 nicotinic receptors, which inhibits nicotine-induced striatal dopamine (DA) release by interacting with α6β2-containing nAChRs [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | 10-14 weeks | |
50 mg | Inquiry | 10-14 weeks |
Description | bPiDI is an innovative selective antagonist of α6β2 nicotinic receptors, which inhibits nicotine-induced striatal dopamine (DA) release by interacting with α6β2-containing nAChRs [1]. |
Molecular Weight | 580.33 |
Formula | C22H34I2N2 |
Cas No. | 525596-64-9 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.